[바이오사 리포트] 쓰리빌리언, 손실폭 줄인 1분기…손익분기점 코앞

3billion is demonstrating a successful transition to a scalable business model as its revenue growth significantly outpaces operational costs, bringing the company closer to its break-even point. The strategic shift toward high-margin genomic services and aggressive expansion into the U.S. market signals a maturing biotech ecosystem where diagnostic data becomes a sustainable commercial asset.